180 Therapeutics LP   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2016
NCT03180957
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

adalimumab (humira) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dupuytren Contracture (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2